|
SERPINC1
|
Thrombophilia
|
0.100 |
Biomarker |
BEFREE |
We demonstrate the feasibility of performing thrombophilia panel testing of enzymatic functional assays on a microfluidic cartridge using low sample volume.Functional assays for Antithrombin III, Protein C, Factor VIII, and plasminogen were adapted on the digital microfluidic platform by developing novel fluorogenic substrates and establishing on-cartridge fluorescence (360/460 nm) detection.
|
29206934 |
2017 |
|
SERPINC1
|
Thrombophilia
|
0.100 |
Biomarker |
BEFREE |
Several genes contribute to thrombophilia, some with major effect (Factor V, Factor II), and some with minor effect (MTHFR, PAI-1, ATIII, etc.).
|
27855570 |
2017 |
|
SERPINC1
|
Thrombophilia
|
0.100 |
GeneticVariation |
BEFREE |
The screening for thrombophilia included mutations of factor V Leiden (FVL), prothrombin (PTM) G20210A, methylene tetrahydrofolate reductase C677T-A1298C, the serum levels of antithrombin III, protein C, protein S, factor VIII and activated protein C resistance.
|
23358198 |
2013 |
|
SERPINC1
|
Thrombophilia
|
0.100 |
GeneticVariation |
BEFREE |
These defects are responsible for only a moderate increase of venous thromboembolism (VTE) risk compared with strong thrombophilias (antithrombin III, protein C and protein S deficiencies and homozygous forms of factor V Leiden and G20210A prothrombin mutation).
|
23026651 |
2012 |
|
SERPINC1
|
Thrombophilia
|
0.100 |
GeneticVariation |
BEFREE |
Patients who had venous thromboembolism after total hip arthroplasty were more likely than matched control patients to have heritable thrombophilia with antithrombin III or protein C deficiency, or homo-heterozygosity for the prothrombin gene mutation.
|
16330983 |
2005 |
|
SERPINC1
|
Thrombophilia
|
0.100 |
Biomarker |
BEFREE |
We carried out serologic measures of thrombophilia (homocysteine, anticardiolipin antibodies [ACLA] immunoglobulin G and immunoglobulin M, lupus anticoagulant, factor VIII, factor XI, protein C, total and free protein S, antithrombin III) and hypofibrinolysis (plasminogen activator inhibitor activity [PAI-Fx], lipoprotein[a]).
|
16154434 |
2005 |
|
SERPINC1
|
Thrombophilia
|
0.100 |
GeneticVariation |
BEFREE |
Testing for factor V Leiden and prothrombin G20210A mutations, homocysteine, anticardiolipin antibodies (ACAs), lupus anticoagulant, and functional assays for protein S, protein C, and antithrombin III were performed to detect a hypercoagulable state.No IRB approval was necessary.
|
12654376 |
2003 |
|
SERPINC1
|
Thrombophilia
|
0.100 |
Biomarker |
BEFREE |
After adjustment for other inherited causes of thrombophilia (deficiency of antithrombin III, protein C or S, factor V Leiden) the overall risk for VTE associated with the prothrombin polymorphism was 3.4 times higher than in the controls (95% CI, 2.0 to 5.8).
|
12551828 |
2003 |
|
SERPINC1
|
Thrombophilia
|
0.100 |
GeneticVariation |
BEFREE |
Prothrombin gene polymorphism G20210A seems to be nonexistent in our population and AT III deficiency also appears to be low compared to other markers of thrombophilia.
|
11292195 |
2001 |
|
SERPINC1
|
Thrombophilia
|
0.100 |
GeneticVariation |
BEFREE |
Extensive assessment excluded the usual causes of SBI and plasma hypercoagulation syndrome (antithrombin III, protein C, and protein S deficiency and myeloproliferative syndrome).
|
9207293 |
1997 |
|
SERPINC1
|
Thrombophilia
|
0.100 |
GeneticVariation |
BEFREE |
We studied the prevalence of antithrombin III (AT III), protein C (PC) and protein S (PS) deficiencies and factor V Leiden mutation in thrombophilia in Taiwan.
|
9271815 |
1997 |
|
SERPINC1
|
Thrombophilia
|
0.100 |
GeneticVariation |
BEFREE |
The clinical history of 238 patients with inherited thrombophilia (AT III = 94, PC = 103, PS = 41) was analyzed retrospectively at diagnosis and in the follow-up period after diagnosis.
|
7855783 |
1994 |
|
SERPINC1
|
Thrombophilia
|
0.100 |
GeneticVariation |
BEFREE |
In 107 asymptomatic and untreated patients with inherited syndromes associated with thrombophilia (antithrombin III, protein C and protein S deficiencies), we compared in parallel two plasma peptides which reflect activation of the common coagulation pathway: the prothrombin fragment 1 + 2 (F1 + 2) and fibrinopeptide A (FPA).
|
1535736 |
1992 |